Acoramidis
Acoramidis is the medicine in Attruby, a tablet sold as acoramidis hydrochloride. The US label calls it a transthyretin stabilizer and says it is a selective stabilizer of transthyretin (TTR), the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization. The atlas holds no trial results for it.
Also called Attruby · Acoramidis hydrochloride
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2698312 (acoramidis); the label names the salt acoramidis hydrochloride (RxNorm 2698313), whose UNII VY9C88C2NV is a broad match to the ingredient. RxClass lists the FDA established pharmacologic class Transthyretin Stabilizer, so the record is filed under the class page. MeSH has no descriptor for acoramidis (an exact-label lookup returned an empty list on 2026-11-19). The label read is the BridgeBio Pharma, Inc. label for Attruby, application NDA216540, effective 2026-06-29 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indication, the class and the mechanism sentences only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says acoramidis is a selective stabilizer of transthyretin (TTR): it binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers.
Classification codes
-
VY9C88C2NVAcoramidis hydrochloride
Claims and evidence
Context Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby
- Recipient
- Recipient not specified
- Population
- Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)
- Excluded
- None stated
The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.
Applies to Recipient not specified Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA216540.
- Retrieved
- Source effective date
- 2026-06-29
- Source state
- Current
- Version fingerprint
438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260629.
- Retrieved
- Source effective date
- 2026-06-29
- Source state
- Current
- Version fingerprint
438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], highlights sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-ACO-LB-04).
- Retrieved
- Source effective date
- 2026-06-29
- Source state
- Current
- Version fingerprint
438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], highlights sentence, benefit
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-ACO-LB-05).
- Retrieved
- Source effective date
- 2026-06-29
- Source state
- Current
- Version fingerprint
438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as an indication: Cardiac amyloidosis
Applies to Recipient not specified Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby
The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:acoramidis- Content hash
9eed0e120ec3b2f3557d5ed715dbb373f512c83990889481de2ce7da1ec29ac7